Aripiprazole associated with severe exacerbation of Parkinson's disease.
Identifieur interne : 001769 ( Ncbi/Merge ); précédent : 001768; suivant : 001770Aripiprazole associated with severe exacerbation of Parkinson's disease.
Auteurs : Mirdhu Wickremaratchi ; Huw R. Morris ; Imad M. AliSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2006.
English descriptors
- KwdEn :
- Antipsychotic Agents (adverse effects), Antipsychotic Agents (therapeutic use), Dyskinesia, Drug-Induced (diagnosis), Female, Humans, Middle Aged, Neurologic Examination (drug effects), Parkinson Disease (drug therapy), Parkinsonian Disorders (chemically induced), Parkinsonian Disorders (diagnosis), Piperazines (adverse effects), Piperazines (therapeutic use), Psychotic Disorders (drug therapy), Quinolones (adverse effects), Quinolones (therapeutic use).
- MESH :
- chemical , adverse effects : Antipsychotic Agents, Piperazines, Quinolones.
- chemical , therapeutic use : Antipsychotic Agents, Piperazines, Quinolones.
- chemically induced : Parkinsonian Disorders.
- diagnosis : Dyskinesia, Drug-Induced, Parkinsonian Disorders.
- drug effects : Neurologic Examination.
- drug therapy : Parkinson Disease, Psychotic Disorders.
- Female, Humans, Middle Aged.
DOI: 10.1002/mds.21025
PubMed: 16817207
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002B68
- to stream PubMed, to step Curation: 002B68
- to stream PubMed, to step Checkpoint: 002E76
Links to Exploration step
pubmed:16817207Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Aripiprazole associated with severe exacerbation of Parkinson's disease.</title>
<author><name sortKey="Wickremaratchi, Mirdhu" sort="Wickremaratchi, Mirdhu" uniqKey="Wickremaratchi M" first="Mirdhu" last="Wickremaratchi">Mirdhu Wickremaratchi</name>
</author>
<author><name sortKey="Morris, Huw R" sort="Morris, Huw R" uniqKey="Morris H" first="Huw R" last="Morris">Huw R. Morris</name>
</author>
<author><name sortKey="Ali, Imad M" sort="Ali, Imad M" uniqKey="Ali I" first="Imad M" last="Ali">Imad M. Ali</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2006">2006</date>
<idno type="doi">10.1002/mds.21025</idno>
<idno type="RBID">pubmed:16817207</idno>
<idno type="pmid">16817207</idno>
<idno type="wicri:Area/PubMed/Corpus">002B68</idno>
<idno type="wicri:Area/PubMed/Curation">002B68</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002E76</idno>
<idno type="wicri:Area/Ncbi/Merge">001769</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Aripiprazole associated with severe exacerbation of Parkinson's disease.</title>
<author><name sortKey="Wickremaratchi, Mirdhu" sort="Wickremaratchi, Mirdhu" uniqKey="Wickremaratchi M" first="Mirdhu" last="Wickremaratchi">Mirdhu Wickremaratchi</name>
</author>
<author><name sortKey="Morris, Huw R" sort="Morris, Huw R" uniqKey="Morris H" first="Huw R" last="Morris">Huw R. Morris</name>
</author>
<author><name sortKey="Ali, Imad M" sort="Ali, Imad M" uniqKey="Ali I" first="Imad M" last="Ali">Imad M. Ali</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2006" type="published">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antipsychotic Agents (adverse effects)</term>
<term>Antipsychotic Agents (therapeutic use)</term>
<term>Dyskinesia, Drug-Induced (diagnosis)</term>
<term>Female</term>
<term>Humans</term>
<term>Middle Aged</term>
<term>Neurologic Examination (drug effects)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinsonian Disorders (chemically induced)</term>
<term>Parkinsonian Disorders (diagnosis)</term>
<term>Piperazines (adverse effects)</term>
<term>Piperazines (therapeutic use)</term>
<term>Psychotic Disorders (drug therapy)</term>
<term>Quinolones (adverse effects)</term>
<term>Quinolones (therapeutic use)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antipsychotic Agents</term>
<term>Piperazines</term>
<term>Quinolones</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antipsychotic Agents</term>
<term>Piperazines</term>
<term>Quinolones</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinsonian Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
<term>Parkinsonian Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Neurologic Examination</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
<term>Psychotic Disorders</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Female</term>
<term>Humans</term>
<term>Middle Aged</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">16817207</PMID>
<DateCreated><Year>2006</Year>
<Month>09</Month>
<Day>27</Day>
</DateCreated>
<DateCompleted><Year>2007</Year>
<Month>02</Month>
<Day>02</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>05</Month>
<Day>27</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN>
<JournalIssue CitedMedium="Print"><Volume>21</Volume>
<Issue>9</Issue>
<PubDate><Year>2006</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
</Journal>
<ArticleTitle>Aripiprazole associated with severe exacerbation of Parkinson's disease.</ArticleTitle>
<Pagination><MedlinePgn>1538-9</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wickremaratchi</LastName>
<ForeName>Mirdhu</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Morris</LastName>
<ForeName>Huw R</ForeName>
<Initials>HR</Initials>
</Author>
<Author ValidYN="Y"><LastName>Ali</LastName>
<ForeName>Imad M</ForeName>
<Initials>IM</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>G-8047</GrantID>
<Agency>Parkinson's UK</Agency>
<Country>United Kingdom</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType>
<PublicationType UI="D016422">Letter</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015363">Quinolones</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>82VFR53I78</RegistryNumber>
<NameOfSubstance UI="C094645">aripiprazole</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014150">Antipsychotic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D004409">Dyskinesia, Drug-Induced</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D009460">Neurologic Examination</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D020734">Parkinsonian Disorders</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D010879">Piperazines</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D011618">Psychotic Disorders</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D015363">Quinolones</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year>
<Month>7</Month>
<Day>4</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2007</Year>
<Month>2</Month>
<Day>3</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2006</Year>
<Month>7</Month>
<Day>4</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="doi">10.1002/mds.21025</ArticleId>
<ArticleId IdType="pubmed">16817207</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list></list>
<tree><noCountry><name sortKey="Ali, Imad M" sort="Ali, Imad M" uniqKey="Ali I" first="Imad M" last="Ali">Imad M. Ali</name>
<name sortKey="Morris, Huw R" sort="Morris, Huw R" uniqKey="Morris H" first="Huw R" last="Morris">Huw R. Morris</name>
<name sortKey="Wickremaratchi, Mirdhu" sort="Wickremaratchi, Mirdhu" uniqKey="Wickremaratchi M" first="Mirdhu" last="Wickremaratchi">Mirdhu Wickremaratchi</name>
</noCountry>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001769 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001769 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Ncbi |étape= Merge |type= RBID |clé= pubmed:16817207 |texte= Aripiprazole associated with severe exacerbation of Parkinson's disease. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:16817207" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \ | NlmPubMed2Wicri -a MovDisordV3
This area was generated with Dilib version V0.6.23. |